Efficacy and Safety of Aclidinium Bromide at Two Dose Levels Versus Placebo Administered in Chronic Obstructive Pulmonary Disease (COPD) Patients

Exclusion Criteria

• •Patients with no history or current diagnosis of asthma.
• •No evidence of an exacerbation within 6 weeks prior to the screening visit.
• •No evidence of clinically significant respiratory and/or cardiovascular conditions or laboratory abnormalities.
• •No contraindication to use of anticholinergic drugs such as known symptomatic prostatic hypertrophy, bladder neck obstruction or narrow-angle glaucoma.